ZYCLARA (imiquimod) by Bausch + Lomb is interferon inducers [moa]. First approved in 2010.
Drug data last refreshed 4h ago · AI intelligence enriched Yesterday
ZYCLARA (imiquimod) is a topical cream formulation of imiquimod, an interferon inducer that activates innate immunity at the application site. It is used to treat external genital warts, actinic keratosis, and superficial basal cell carcinoma. The drug works by stimulating local interferon production and immune cell activation to clear viral or malignant lesions.
Product is at peak maturity with modest Medicare spending; commercial team is likely optimized for maintenance rather than expansion.
Interferon Inducers
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers
Worked on ZYCLARA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
Working on ZYCLARA represents a mature product role with focus on market maintenance, competitive positioning, and LOE planning. Career growth will pivot toward strategic initiatives such as indication expansion, formulation improvements, or transition into post-LOE portfolio management.